Notch1 can contribute to viral-induced transformation of primary human keratinocytes

The human papillomavirus (HPV) is the most significant causative agent in the development of cervical cancer. Despite its presence in almost all cervical cancers, HPV by itself is unable to transform a normal cell to a cancerous one. Instead, additional cellular mutations are required to supplement the HPV oncoproteins E6 and E7. Activation of the Notch1 signaling pathway has been proposed as one of the cellular changes that cooperate with the E6 and E7 proteins to cause cervical cancers. This proposition is based on: (a) the detection of active Notch1 in high-grade cervical lesions and cancers; (b) the synergism between Notch1 and E6 and E7 to transform immortalized cells; and (c) the obliteration of neoplastic properties of a cervical cancer cell line when Notch1 expression was inhibited. However, this view was put in doubt by a recent report that showed Notch1 expression is markedly reduced in cervical cancer cells, and this was attributed to the ability of Notch1 to repress the expression of the HPV E6 and E7 proteins. Here we report that although exaggerated levels of Notch1 can, indeed, adversely affect HPV E6 and E7 expression, and cellular proliferation in general, moderate levels of Notch1, together with active phosphoinositide 3 kinase, can, instead, exhibit oncogenic properties that transform primary cells containing HPV16 E6 and E7 proteins. In addition, we show that activated Notch1 is readily detected in all cervical cancer cell lines tested. Together, these results show that not only do cervical cancer cells express Notch1, but also that Notch1 signaling, in synergy with other cellular changes, can participate in the transformation of primary cells expressing E6 and E7 proteins

gamma-secretase inhibitors exerts antitumor activity via down-regulation of Notch and Nuclear factor kappa B in human tongue carcinoma cells

Objective To investigate the effect of the gamma-secretase inhibitors (GSIs) on the growth of human tongue carcinoma cells and to provide the molecular mechanism for potential application of GSIs in the treatment of tongue carcinoma. Materials and Methods Human tongue carcinoma Tca8113 cells were cultured with the GSI L-685 458. Cell growth was determined by the methylthiazole tetrazolium method. Cell cycle and apoptosis were analyzed by flow cytometry and/or confocal microscopy. RT-PCR and Western blot were employed to determine the intracellular expression levels. Nuclear factor kappa B (NF-kappa B) activation was examined by electrophoretic mobility shift assay. Results L-685,458 dose-dependently inhibited the growth of human tongue carcinoma Tca8113 cells by inducing G0-G1 cell cycle arrest and apoptosis. The mRNA and protein levels of Hairy/Enhancer of Split-1, a target of Notch activation, were decreased dose-dependently by L-685,458. Furthermore, L-685,458 down-regulated cyclin D1, B-cell lymphocytic-leukemia proto-oncogene 2 and c-Myc expressions, which are regulated by the transcription factor NF-kappa B. Coincident with this observation, L-685,458 induced a dose-dependent reduction of constitutive NF-kappa B activation in Tca8113 cells. Conclusions The GSI L-685,458 may have a therapeutic value for the treatment of human tongue carcinoma. Moreover, the effects of L-685,458 in tumor inhibition may act partially via the modulation of Notch and NF-kappa B